• OliX Pharmaceuticals corrected an earlier disclosure on its OLX10212 Phase 2a trial plan in geographic atrophy secondary to AMD.
• The revision adds a New Zealand MedSafe clinical trial application filed on Sept. 30, 2026, alongside the previously disclosed Australian ethics submission.
• Planned trial footprint now includes up to three sites in New Zealand, in addition to up to six sites in Australia.
• The company expects to file a separate disclosure once MedSafe clears the trial plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900334), on September 30, 2026, and is solely responsible for the information contained therein.